e-learning
resources
Berlin 2001
Sunday 23.09.2001
Inflammation, infection and exercise capacity in cystic fibrosis patients
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Comparative efficacy of different methods of ceftazidime administration in children with cystic fibrosis
S. M. Shatunov (Moscow, Russia)
Source:
Annual Congress 2001 - Inflammation, infection and exercise capacity in cystic fibrosis patients
Session:
Inflammation, infection and exercise capacity in cystic fibrosis patients
Session type:
Thematic Poster Session
Number:
860
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. M. Shatunov (Moscow, Russia). Comparative efficacy of different methods of ceftazidime administration in children with cystic fibrosis. Eur Respir J 2001; 16: Suppl. 31, 860
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
The pharmacokinetic of the main oral antibiotics in children with cystic fibrosis.
Source: International Congress 2019 – Treatments, adherence and psychosocial aspects of cystic fibrosis
Year: 2019
Once-daily tobramycin in the treatment of adult patients with cystic fibrosis
Source: Eur Respir J 2002; 19: 303-309
Year: 2002
Long-term administration of aerosolised tobramycin in patients with cystic fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 619s
Year: 2005
Long-term efficacy and safety of tobramycin 300mg/4mL nebuliser solution in patients with cystic fibrosis and chronic
Pseudomonas aeruginosa
infection
Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis
Year: 2012
Pharmacokinetics of oral voriconazole in adults with cystic fibrosis
Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more
Year: 2010
Safety and efficacy of intravenous (IV) Fosfomycin in adult cystic fibrosis patients
Source: International Congress 2018 – Latest developments in cystic fibrosis
Year: 2018
Interim data from a long-term safety, tolerability, and efficacy study of liposomal amikacin for inhalation in cystic fibrosis patients with chronic
pseudomonas aeruginosa
infection
Source: International Congress 2014 – Cystic fibrosis: assessment and treatment
Year: 2014
Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in cystic fibrosis (CF) patients
Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies
Year: 2009
Efficacy of low-dose, long-term clarithromycin administration in improving the clinical course in cystic fibrosis patients with chronic
P. aeruginosa
airway colonization
Source: Eur Respir J 2003; 22: Suppl. 45, 514s
Year: 2003
Formulation of dual modality nanoparticles to enhance tobramycin efficacy in cystic fibrosis
Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways
Year: 2013
A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis
Source: Eur Respir J 2002; 20: 658-664
Year: 2002
Daily versus weekly azithromycin in cystic fibrosis patients
Source: Eur Respir J 2007; 30: 487-495
Year: 2007
Effects of long-term azithromycin treatment in patients with non-cystic fibrosis stable bronchiectasis
Source: Annual Congress 2007 - Infectious lung and pleural diseases
Year: 2007
A randomised comparison of two tobramycin formulations in cystic fibrosis (CF) patients with chronic
pseudomonas aeruginosa
(PA) infection for pharmacokinetic and therapeutic equivalence
Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science
Year: 2013
Home intravenous antibiotic treatments in cystic fibrosis adult patients
Source: Eur Respir J 2002; 20: Suppl. 38, 158s
Year: 2002
An anti-inflammatory effect of azithromycin in cystic fibrosis
Source: Annual Congress 2010 - New aspects of cystic fibrosis
Year: 2010
Possible mechanisms of action of azithromycin in cystic fibrosis
Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle
Year: 2005
A UK experience of temocillin in the treatment of adult cystic fibrosis patients
Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools
Year: 2008
Clinical efficacy data for new diagnostic tool for the selection of the most effective antibiotics for patients with cystic fibrosis
Source: Virtual Congress 2020 – Microbiology and antimicrobial strategies in cystic fibrosis
Year: 2020
The role of inhaled antibiotics in bronchial infection
Source: Eur Respir Monogr 2013; 60: 120-126
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept